<DOC>
	<DOCNO>NCT00387322</DOCNO>
	<brief_summary>RATIONALE : Pemetrexed disodium erlotinib may stop growth tumor cell block enzymes need cell growth . Giving pemetrexed disodium together erlotinib may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose two different schedule pemetrexed disodium erlotinib see well work treat patient advance non-small cell lung cancer solid tumor .</brief_summary>
	<brief_title>Pemetrexed Disodium Erlotinib Treating Patients With Advanced Non-Small Cell Lung Cancer Other Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety feasibility combine pemetrexed disodium erlotinib hydrochloride patient advance non-small lung cancer ( NSCLC ) solid tumor . ( Phase I ) - Determine response rate patient NSCLC treat pemetrexed disodium combination erlotinib hydrochloride . ( Phase II ) Secondary - Compare toxicity difference different schedule pemetrexed disodium erlotinib hydrochloride . ( Phase I ) - Determine maximum tolerate dose ( MTD ) 2 different schedule pemetrexed disodium erlotinib hydrochloride . ( Phase I ) - Determine , preliminarily , efficacy combination pemetrexed disodium erlotinib hydrochloride patient advance solid tumor . ( Phase I ) - Assess overall survival progression-free survival . ( Phase II ) - Determine frequency severity toxicity associate administration pemetrexed disodium erlotinib hydrochloride . ( Phase II ) OUTLINE : This multicenter , phase I dose-escalation study follow phase II open-label study . - Phase I : Patients assign 1 2 treatment group alternate fashion . Once accrual first dose level group 1 complete , group 2 open accrual first dose level . - Group 1 : Patients receive oral erlotinib hydrochloride day 2 , 9 , 16 pemetrexed disodium IV 10 minute day 1 . Treatment repeat every 21 day 6 course absence unacceptable toxicity disease progression . - Group 2 : Patients receive oral erlotinib hydrochloride daily day 2-16 pemetrexed disodium IV 10 minute day 1 . Treatment repeat every 21 day 6 course absence unacceptable toxicity disease progression . In group , patient may continue receive erlotinib hydrochloride alone completion 6 course erlotinib hydrochloride combination pemetrexed disodium . In group , cohort 3-6 patient receive escalate dos erlotinib hydrochloride pemetrexed disodium maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive pemetrexed disodium MTD erlotinib hydrochloride MTD group 1 2 ( whichever favorable ) . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 92 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>For phase I portion study patient must cytologically histologically proven advanced solid tumor standard effective therapy available . For phase II portion patient must cytologically histologically proven select stage IIIB ( pleural effusion ) IV NSCLC . Patients NSCLC progress recurred firstline therapy stage IIIA IIIB may also consider . For phase II portion patient must disease progressed recur treatment platinumbased therapy . Any number prior chemotherapy regimen allow phase I portion 1 previous treatment advance NSCLC allow phase II portion . Patients must measurable disease RECIST criterion . Disease previously irradiate site consider measurable clear disease progression follow radiation therapy . Patients evaluable disease ( bone metastasis , pleural fluid , ascites , etc . ) may include phase I portion trial . Patients must 18 year age old . Patients must performance status 02 phase I portion study performance status 0 1 phase II portion trial . Patients must estimate survival least 3 month . Any prior chemotherapy patient receive complete least 4 week prior start treatment . For prior mitomycin chemotherapy 6week interval require . Prior radiation must complete least 2 week prior start therapy . Patients must recover acute reversible side effect prior chemotherapy regimen radiotherapy NCICTC &lt; grade 1 ( exclude alopecia ) . Patients must adequate renal function document serum creatinine &lt; 1.5 mg/dl calculate creatinine clearance &gt; 45 ml/min ( see appendix formula calculate creatinine clearance ) . Patients must adequate liver function document serum bilirubin &lt; 1.5 x ULN . AST must &lt; 2.5 x institutional upper limit normal . Patients must pretreatment granulocyte count &gt; 1500/mm3 platelet count &gt; 100 000/mm3 . Patients asymptomatic treat brain metastasis ( surgical resection radiotherapy ) may include neurologically stable steroid anticonvulsant least 4 week . Because possibility treatment related neurological toxicity difficult evaluate toxicity presence symptomatic brain metastasis . All patient must give voluntary write informed consent . Patients must able take retain oral medication . Patients reproductive potential must agree use effective contraceptive method treatment 3 month afterwards effect drug unborn fetus unknown . Patients coumadin INR monitor least per week frequently depend investigator judgement . There case report increase INR coumadin coadministered OSI774/placebo . Patients may previously receive Pemetrexed EGFRdirected therapy . Females pregnant breastfeeding effect drug unborn fetus unknown . Documentation negative serum pregnancy test require woman reproductive potential . Patients symptomatic brain metastasis still require steroid anticonvulsant may include . No prior malignancy allow phase II portion except follow : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated stage I II cancer patient currently complete remission , cancer patient diseasefree five year . Patients take nonsteroidal antiinflammatory agent ( NSAIDS ) salicylates 2 day prior 2 day follow ( 5 day pre post longacting NSAIDS ) administration pemetrexed due concern increase risk renal toxicity . Patients clinically significant ophthalmologic abnormality exclude . This include severe dry eye syndrome , keratoconjunctivitis sicca , Sjogren 's syndrome , severe exposure keratopathy , disorder might increase risk corneal epithelial injury .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>